Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment.

Lyritis GP, Magiasis B, Tsakalakos N

Calcified tissue international1 Jan 1995Cited by 13 (Europe PMC)

PMID7796344DOI10.1007/bf00298742PepBankPUB-07796344

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialSafety outcome
In high-turnover early postmenopausal women, nasal mucosa discomfort occurred in one salmon calcitonin recipient and one placebo recipient.
In plain wordsIn early postmenopausal women, nasal discomfort occurred in one salmon calcitonin recipient and one placebo recipient.
Peptide
Calcitonin-salmon
Outcome
Not applicableNasal mucosa discomfort
Study
n = 56
Comparator
Placebo
Outcome group
Adverse events · Respiratory
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
No other side effects were noted apart from discomfort of nasal mucosa in two patients (one in each group).
4 context sentences(design, population, supporting numbers)
Summary · context
Fifty-six women were characterized as high turnover patients (estimated annual bone loss more than 2.7%).
Summary · context
These high turnover patients were included in a double-blind, placebo-controlled clinical study.
Summary · context
Patients were divided into two groups of 28 women each.
Summary · context
The first group of patients received 100 IU of salmon calcitonin intranasally daily for 1 year and the second group intranasal spray of placebo daily.
Report a problemFND-0779634401
02HumanNon-randomized trialSafety outcome
In high-turnover early postmenopausal women given salmon calcitonin or placebo, no side effects other than nasal mucosa discomfort were noted.
In plain wordsIn early postmenopausal women given salmon calcitonin or placebo, no side effects other than nasal discomfort were noted.
Peptide
Calcitonin-salmon
Outcome
Not applicableOther side effects
Study
n = 56
Outcome group
Adverse events · Whole body
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
No other side effects were noted apart from discomfort of nasal mucosa in two patients (one in each group).
4 context sentences(design, population, supporting numbers)
Summary · context
Fifty-six women were characterized as high turnover patients (estimated annual bone loss more than 2.7%).
Summary · context
These high turnover patients were included in a double-blind, placebo-controlled clinical study.
Summary · context
Patients were divided into two groups of 28 women each.
Summary · context
The first group of patients received 100 IU of salmon calcitonin intranasally daily for 1 year and the second group intranasal spray of placebo daily.
Report a problemFND-0779634402
03HumanNon-randomized trialEfficacy outcome
In high-turnover early postmenopausal women, salmon calcitonin reduced estimated bone loss rate from 3.7% to 0.8% at 6 months.
In plain wordsIn early postmenopausal women, salmon calcitonin reduced estimated bone loss rate from baseline at 6 months.
Peptide
Calcitonin-salmon
Outcome
DecreaseEstimated bone loss rate at 6 months
Study
n = 28
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Measurements
Baseline bone loss rate
3.7%
calcitonin
Bone loss rate
0.8%
6 months
Source sentences
Summary
The group of calcitonin-treated patients showed a dramatic decrease in bone loss rate as estimated with the use of biochemical bone markers at the end of 6 and 12 months (3.7% versus 0.8% and 0.0% at the end of 6 and 12 months, respectively, P < 0.001) whereas in the placebo group, bone loss rate re…
4 context sentences(design, population, supporting numbers)
Summary · context
Fifty-six women were characterized as high turnover patients (estimated annual bone loss more than 2.7%).
Summary · context
These high turnover patients were included in a double-blind, placebo-controlled clinical study.
Summary · context
Patients were divided into two groups of 28 women each.
Summary · context
The first group of patients received 100 IU of salmon calcitonin intranasally daily for 1 year and the second group intranasal spray of placebo daily.
Report a problemFND-0779634403
04HumanNon-randomized trialEfficacy outcome
In high-turnover early postmenopausal women, salmon calcitonin reduced estimated bone loss rate from 3.7% to 0.0% at 12 months.
In plain wordsIn early postmenopausal women, salmon calcitonin reduced estimated bone loss rate from baseline at 12 months.
Peptide
Calcitonin-salmon
Outcome
DecreaseEstimated bone loss rate at 12 months
Study
n = 28
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Measurements
Baseline bone loss rate
3.7%
calcitonin
Bone loss rate
0%
12 months
Source sentences
Summary
The group of calcitonin-treated patients showed a dramatic decrease in bone loss rate as estimated with the use of biochemical bone markers at the end of 6 and 12 months (3.7% versus 0.8% and 0.0% at the end of 6 and 12 months, respectively, P < 0.001) whereas in the placebo group, bone loss rate re…
4 context sentences(design, population, supporting numbers)
Summary · context
Fifty-six women were characterized as high turnover patients (estimated annual bone loss more than 2.7%).
Summary · context
These high turnover patients were included in a double-blind, placebo-controlled clinical study.
Summary · context
Patients were divided into two groups of 28 women each.
Summary · context
The first group of patients received 100 IU of salmon calcitonin intranasally daily for 1 year and the second group intranasal spray of placebo daily.
Report a problemFND-0779634404
05HumanNon-randomized trialEfficacy outcome
In high-turnover early postmenopausal women, salmon calcitonin significantly increased spine bone mineral content.
In plain wordsIn early postmenopausal women, salmon calcitonin increased spine bone mineral content from baseline.
Peptide
Calcitonin-salmon
Outcome
IncreaseSpine bone mineral content
Study
n = 28
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
The calcitonin-treated patients showed a significant increase in bone mineral content of spine and proximal forearm (P < 0.001 at the end of 6 and 12 months, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
Fifty-six women were characterized as high turnover patients (estimated annual bone loss more than 2.7%).
Summary · context
These high turnover patients were included in a double-blind, placebo-controlled clinical study.
Summary · context
Patients were divided into two groups of 28 women each.
Summary · context
The first group of patients received 100 IU of salmon calcitonin intranasally daily for 1 year and the second group intranasal spray of placebo daily.
Report a problemFND-0779634405
06HumanNon-randomized trialEfficacy outcome
In high-turnover early postmenopausal women, salmon calcitonin significantly increased proximal forearm bone mineral content.
In plain wordsIn early postmenopausal women, salmon calcitonin increased forearm bone mineral content from baseline.
Peptide
Calcitonin-salmon
Outcome
IncreaseProximal forearm bone mineral content
Study
n = 28
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 IU daily · intranasal · 1 yearAs given in this study (human).
Source sentences
Summary
The calcitonin-treated patients showed a significant increase in bone mineral content of spine and proximal forearm (P < 0.001 at the end of 6 and 12 months, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
Fifty-six women were characterized as high turnover patients (estimated annual bone loss more than 2.7%).
Summary · context
These high turnover patients were included in a double-blind, placebo-controlled clinical study.
Summary · context
Patients were divided into two groups of 28 women each.
Summary · context
The first group of patients received 100 IU of salmon calcitonin intranasally daily for 1 year and the second group intranasal spray of placebo daily.
Report a problemFND-0779634406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.